Icosapent Ethyl
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
Icosapent Ethyl: From an Unrecorded Original Indication to Hemoglobinopathy
One-Sentence Summary
Icosapent ethyl is a purified omega-3 fatty acid (EPA ethyl ester) that is marketed in the United States, but the Evidence Pack does not record its original indication. The TxGNN model predicts it may be useful for hemoglobinopathy, with 0 clinical trials and 1 publication currently supporting this direction. That publication is a mouse study of a different omega-3 compound, so the evidence is weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the Evidence Pack |
| Predicted New Indication | Hemoglobinopathy |
| TxGNN Prediction Score | 99.09% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (the licenses listed are ANDAs) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Icosapent ethyl is a purified EPA ethyl ester, an omega-3 fatty acid. Its original indication is not recorded in this dataset, so the link between the original and new indication cannot be assessed directly.
The only support is indirect. Omega-3 fatty acids may reduce inflammation, oxidative stress and vaso-occlusive injury, which are relevant to hemoglobinopathies such as sickle cell disease. In the one retrieved paper, epeleuton, a different synthetic omega-3 fatty acid, reduced hypoxia/reperfusion stress in a mouse model. The title is truncated, so the model is presumably sickle cell disease, but the data do not confirm this.
This has not been shown for icosapent ethyl, and the epeleuton results cannot be assumed to transfer to it. The TxGNN score is a knowledge-graph prediction, not clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38105727 | 2024 | Preclinical animal study | Haematologica | Epeleuton, a different synthetic omega-3 fatty acid, reduced hypoxia/reperfusion stress in a mouse model. It was proposed as a way to target inflammatory vasculopathy. The abstract in the pack is truncated. |
US Market Information
The Evidence Pack lists no approved indication text for these products.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA209525 | Icosapent Ethyl | Capsule, liquid filled | AvKARE |
| ANDA209457 | Icosapent Ethyl | Capsule | Hikma Pharmaceuticals USA Inc. |
| ANDA209437 | Icosapent Ethyl | Capsule | Apotex Corp |
| ANDA209499 | Icosapent Ethyl | Capsule | Dr. Reddy’s Laboratories, Inc. |
All listed forms are oral. Of the 20 authorizations in total, the pack shows only these four distinct ones.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a high model score and one preclinical paper about a different compound. There are no clinical trials, no mechanism data and no recorded original indication. This is a research question, not yet a development candidate.
To proceed, the following is needed:
- Package insert warnings and contraindications, which are required for safety screening
- Mechanism of action data for icosapent ethyl (for example, from DrugBank)
- The original approved indication, to define the relationship to the new indication
- Drug-specific evidence, such as preclinical studies of EPA or icosapent ethyl in sickle cell disease or other hemoglobinopathies
- Confirmation of which hemoglobinopathy the paper studied, since the title is truncated
- A search for related trials in other registries, since none were found
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.